Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00386152 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Terminated
- Registry status
- Phase 2
- Development phase
- 235
- Enrollment target
NCT00386152 is a Phase 2 study that was terminated before completion, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 235 participants.
The verdict
NCT00386152, a Phase 2 study, was terminated before completion, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 235 participants
- Enrollment target
Study Summary
The purpose of this study is to compare hemoglobin response rates between two PROCRIT (epoetin alfa) doses and ARANESP (darbepoetin alfa) in anemic cancer patients receiving chemotherapy
Interventions
- DRUG darbepoetin alfa
- DRUG epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00386152
The ClinicalTrials.gov registry entry for NCT00386152 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which darbepoetin alfa is the first listed.
NCT00386152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00386152 about?
NCT00386152 is a clinical study titled "A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy". The purpose of this study is to compare hemoglobin response rates between two PROCRIT (epoetin alfa) doses and ARANESP (darbepoetin alfa) in anemic cancer patients receiving chemotherapy
What is the current status of trial NCT00386152?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 235 participants. The study started on 2006-11. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00386152?
The interventions under investigation include: darbepoetin alfa (DRUG), epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00386152?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.